Commentary|Articles|August 10, 2026

The AUA Clinically Localized Prostate Cancer guideline: FAQs for urologists

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The American Urological Association (AUA)'s guideline on clinically localized prostate cancer was amended in 2026 to sharpen its recommendations on risk stratification, staging, and risk-based management, while incorporating new evidence on imaging and systemic therapy intensification for higher-risk disease.¹ The updates touch nearly every stage of the care pathway, from how patients are risk-stratified at diagnosis through how they are followed after treatment.

Related to this article

October 21st, 2026

Q&A: Jeffrey Spier, MD, on ARPI fatigue and the case for dose reduction

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

October 19th, 2026

Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

October 19th, 2026

Managing ARPI-related fatigue: Balancing tolerability and treatment persistence

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

October 13th, 2026

Matching mCSPC treatment to the patient, not just the trial data

Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.

October 12th, 2026

Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

October 9th, 2026

FDA grants fast track designation to VIR-5500 for mCRPC

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

October 6th, 2026

Experts review evidence on testosterone and prostate cancer

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

October 6th, 2026

Carotuximab plus apalutamide shows interim PFS benefit in mCRPC

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.